Printer Friendly

SANOFI DIAGNOSTICS PASTEUR PLANS TO MARKET 'ACCESS' IMMUNOASSAY SYSTEM, FEATURING UNIQUE CONTINUOUS TESTING FLEXIBILITY

SANOFI DIAGNOSTICS PASTEUR PLANS TO MARKET 'ACCESS' IMMUNOASSAY SYSTEM,
 FEATURING UNIQUE CONTINUOUS TESTING FLEXIBILITY
 CHASKA, Minn., July 21 /PRNewswire/ -- Sanofi Diagnostics Pasteur, a worldwide leader in the diagnostics testing field, today announced that it plans to distribute its ACCESS(R) Immunoassay System beginning in early 1993, pending regulatory clearance.
 Developed by scientists and researchers at Sanofi Diagnostics Pasteur research facilities in Chaska, Minn.; Seattle; Wash.; and Marnes La Coquette, France, the ACCESS System employs dioxetane-based chemiluminescent technology to measure dozens of blood analytes used in medical diagnoses. The ACCESS System is designed to allow continuous operation 24 hours a day, and it provides highly reliable results at a rate of up to 100 tests per hour. Simple to use, the analyzer measures 39 inches by 18.5 inches by 24 inches, making the compact ACCESS System one-half the size of comparable analyzers; accordingly, it takes up little valuable laboratory bench space.
 A unique carousel design allows continuous placement of additional samples, replenishment of reagents, and enhances positive patient identification. A single, multi-function "pipetting" probe employs ultrasound technology to mix reagents, sense the level of fluids, and minimize "carryover" for improved results. The design eliminates a multitude of moving parts, making the ACCESS System reliable and easy to maintain and service.
 The ACCESS System's ability to allow continuous random-access testing will make it more useful to physicians and laboratory staff, said Terrance J. Bieker, president, Sanofi Diagnostics Pasteur, Inc.
 "No other system combines this level of automated performance and operational simplicity," Bieker said. "Operation consists of two steps -- loading samples and selecting tests. The reduction in labor and the increased productivity that this system offers the laboratory is unparalleled."
 The announcement of the planned launch of the ACCESS System was made this morning at the American Association for Clinical Chemistry convention in Chicago, where Sanofi Diagnostics Pasteur introduced the innovative immunoassay system. The ACCESS System is currently available for conducting clinical trials and research investigations. The company plans to distribute the ACCESS System in major markets beginning in early 1993.
 The ACCESS System test menu will include assays for blood virus, infectious diseases, thyroid function, anemia, fertility, metabolic hormones, cardio-vascular, cancer, and therapeutic drug monitoring. The assay menu will expand rapidly during the next few years as the result of Sanofi Diagnostics Pasteur's worldwide research and development efforts.
 "The ACCESS System was designed to serve the needs of laboratory professionals, physicians, nurses and patients," Bieker said. "It is a true breakthrough in immunoassay technology and design, allowing more rapid completion of laboratory tests and timely diagnosis."
 Sanofi Diagnostics Pasteur is a worldwide joint venture between Sanofi Pharma and the Institut Pasteur. North America-based companies under the international Sanofi Diagnostics Pasteur banner include Sanofi Diagnostics Pasteur, Inc., of Chaska, Minn.; Sanofi Diagnostics Pasteur Canada, Inc., of Montreal; Bigaux Diagnostica S.A. of Benito Juarez, Mexico; and Genetic Systems Corporation of Redmond, Wash., a leading manufacturer and marketer of AIDS tests.
 Sanofi Pharma is the healthcare division of Elf Sanofi S.A., a member of the Societe Nationale Elf Aquitaine group.
 -0- 7/21/92
 /CONTACT: Harry Norris, 612-368-1210, or Jim Fusilli, 212-476-9314, both of Elf Sanofi/ CO: Sanofi Pharma; Institut Pasteur ST: Minnesota, New York, Washington, Illinois IN: MTC SU:


GK-LR -- NY041 -- 1258 07/21/92 11:07 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 21, 1992
Words:547
Previous Article:INTERNATIONAL GAMING MANAGEMENT ACCEPTS INITIAL BALLY VIDEO LOTTERY TERMINALS FOR LOUISIANA START UP
Next Article:GERMAN EXPORTS WILL GROW WITH ECONOMIC RECOVERY
Topics:


Related Articles
SANOFI DIAGNOSTICS PASTEUR TO INTRODUCE INNOVATIVE IMMUNOASSAY SYSTEM AT AACC CONVENTION
SANOFI DIAGNOSTICS PASTEUR TO BECOME SOLE SUPPLIER OF BLOOD SCREEN PRODUCTS TO CANADIAN RED CROSS SOCIETY
ABBOTT LABORATORIES MEETS CHALLENGES OF LABORATORY MEDICINE WITH NEW THIRD-GENERATION INSTRUMENT
PASTEUR SANOFI DIAGNOSTICS AND CENTOCOR SIGN DISTRIBUTION AGREEMENT
SANOFI DIAGNOSTICS PASTEUR ADDS CHLAMYDIA TEST TO ITS ACCESS IMMUNOASSAY SYSTEM
COURT DECISION CLEARS WAY FOR CAMBRIDGE BIOTECH TO FORMULATE REORGANIZATION PLAN
Sanofi Diagnostics Pasteur Signs a Divestment and Alliance Agreement With Beckman Instruments, Inc. on the Automated ACCESS Immunoassay System
Sanofi Diagnostics Pasteur to Construct Major Manufacturing and Distribution Plant in Woodinville, Washington
Ortho-Clinical Diagnostics, a Johnson & Johnson Company: Ten New Assays Propel VITROS(R) Systems to Forefront of Laboratory Instrumentation.
Immunodiagnostic revolution.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters